
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
San Francisco - A fuller understanding of the pathophysiologic processes of pruritus associated with atopic dermatitis (AD) may yield effective new therapies, Martin Steinhoff, M.D., Ph.D. said at the annual meeting of the American Academy of Dermatology.






